Japan firm starts Down's therapy test

July 1, 2013

A Japanese pharmaceutical company said Monday it will begin therapeutic testing of a drug it hopes will slow the decline in quality of life for some people with Down's syndrome.

The firm will trial its "Aricept" donepezil hydrochloride drug, commonly used to treat some of the symptoms of Alzheimer's disease, on people between the ages of 15 and 39 who have Down's syndrome.

Down's is a frequently characterised by diminished mental faculty and , including distinctive facial features.

It is caused by a chromosome defect and is proportionately more common in people born of .

From the mid-teens onwards, roughly six percent of people with Down's syndrome lose physical co-ordination, experience and become more withdrawn, a spokesman for pharmaceutical company Eisai said.

"This testing, if effective, might show that the medication could improve their condition and help improve the quality of their lives," the spokesman said.

It could also ease the burden on their caregivers, he added.

Some of the symptoms experienced by people with Down's syndrome are common to some sufferers of Alzheimer's, for which Aricept has long been prescribed.

The testing will initially involve 10 hospitals across Japan, with dozens of people in the affected age group.

The programme will continue for up to four years, the spokesman said.

The drug is not intended to treat the underlying condition, he said, rather it is hoped it will target some of the symptoms.

Around one in every 830 newborns in the United States has Down's syndrome, according to the National Institutes of Health. This equates to about 250,000 people in the US population, it says.

Explore further: Lilly stops mid-stage Alzheimer's drug study (Update)

Related Stories

Lilly stops mid-stage Alzheimer's drug study (Update)

June 13, 2013
Eli Lilly and Co. said Thursday that it stopped a mid-stage clinical trial of an experimental Alzheimer's disease drug because of potential side effects on patients' livers.

Down syndrome trial may hold key to learning

March 26, 2013
(Medical Xpress)—An ingredient used for decades in cough syrup, and to treat a variety of conditions, could hold the key to improving memory, language, and learning in people with Down syndrome.

UCI study reveals why Down syndrome boosts susceptibility to other conditions

January 11, 2013
A study led by UC Irvine researchers has revealed some of the underlying neural factors that explain why people with Down syndrome are more susceptible to Alzheimer's disease, diabetes and autistic spectrum disorders.

Complex genetic architectures: Some common symptoms of trisomy 21

June 26, 2013
Down syndrome, more commonly known as "trisomy 21" is very often accompanied by pathologies found in the general population: Alzheimer's disease, leukemia, or cardiac deficiency. In a study conducted by Professor Stylianos ...

Lilly drug chosen for Alzheimer's prevention study (Update)

January 18, 2013
Researchers have chosen an experimental drug by Eli Lilly & Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it.

Scientist tests promising drug on those with Down syndrome

August 2, 2011
(PhysOrg.com) -- A University of Colorado School of Medicine scientist is finishing a major clinical trial on a drug that could boost cognitive function in those with Down syndrome, significantly improving their quality of ...

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.